Tilray shares technical analysis: Downtrend persists as $2.88 support comes into focus

Traders Union
All News
Stocks
Tilray drops 3.59% today to $3.09

Highlights

Tilray Brands received approval from Portugal’s INFARMED to conduct onsite cannabis testing, enabling faster batch releases and lower external testing expenses.
The company posted fiscal 2026 revenue of about $915.5 million with a net loss of $122.6 million and improved gross margins.
Shares of Tilray Brands trade below key moving averages with strong selling pressure, an oversold technical condition, and an expected range of $2.88 to $3.3 in coming days.

Operational efficiencies rise following Portuguese regulatory approval

On October 13, Tilray Brands received authorization from Portugal’s INFARMED to carry out microbiological and chemical/physical testing at its Cantanhede medical cannabis facility, a move that enables quicker batch releases and should reduce third-party testing costs, according to MarketBeat. This regulatory approval allows Tilray to streamline production processes and enhance operational efficiency, particularly in the European market. Additionally, the company reported fiscal year 2026 revenue of approximately $915.5 million, a net loss of roughly $122.6 million, and improved margins alongside stable balance sheet metrics, though price action has remained under broader selling pressure.

Bearish pressures intensify as technicals confirm oversold state

TLRY is sitting below specific technical markers with hourly price remaining under the MA-20 at $3.19, MA-50 at $3.36, and the longer-term MA-200 at $5.83. The Ichimoku Kijun at $3.22 is acting as immediate resistance, while support is identified around $2.88. Momentum indicators confirm the bearish structure: MACD and ADX highlight strong selling pressure, RSI at 29.8 and CCI both indicate oversold territory, and Stoch RSI is in a neutral state. Intraday, Bull/Bear Power and the Awesome Oscillator confirm that sellers retain control in the current setup.

Downside risk prevails amid persistent selling and weak support

Over the next several sessions, TLRY is expected to trade between $2.88 and $3.3, a volatility band relative to current levels. The prospects for an upward move are considered very low given prevailing momentum, whereas a further decline carries high probability if support at $2.88 fails. The baseline calls for price to remain constrained by selling pressure within this band. Should the stock decisively break above the $3.22 resistance, it could signal the start of stabilization; however, a move beneath $2.88 risks additional downside as sellers press the advantage.

Viktoras Karapetjanc, expert at Traders Union, sees recent regulatory progress in Europe as a constructive driver for Tilray. He believes improved operational efficiency and financial discipline are building a solid base, despite the current negative price momentum. However, sentiment remains under pressure and technicals point to persistent selling unless key resistance at $3.22 is reclaimed. "If Tilray can sustain operational improvements and the price holds above support, the groundwork is set for a medium-term turnaround."

Previously it was reported that analysts continued to flag Tilray's persistent technical weaknesses and elevated downside risk amid tightening financial conditions. The current article strengthens this view by highlighting that, despite recent regulatory progress and operational improvements, traders should closely monitor the $2.88 support as failure to hold this level could accelerate further declines.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.